SCHEDULE: T. Rowe Price Boosts INSMED Stake to 5.9%

T. Rowe Price Associates, Inc. reported an aggregate beneficial ownership of 5.9% of INSMED INC's common stock as of June 30, 2025.

Summary

• T. Rowe Price Associates, Inc. filed an Amendment No. 14 to Schedule 13G regarding its beneficial ownership in INSMED INC.
• As of June 30, 2025, T. Rowe Price Associates, Inc. beneficially owned an aggregate of 11,230,934 shares of INSMED INC's common stock.
• This ownership represents 5.9% of the total outstanding common stock of INSMED INC.
• T. Rowe Price Associates, Inc. holds sole voting power over 10,918,453 shares and sole dispositive power over 11,188,173 shares.
• No shared voting or dispositive power was reported.

Sentiment

Score: 6

Explanation: The filing is a routine disclosure of institutional ownership, which is generally neutral but can be seen as a positive signal of investor confidence due to the significant stake held by a reputable firm.

Positives

• The continued significant holding by a major institutional investor like T. Rowe Price Associates, Inc. (5.9%) can be interpreted as a positive signal of confidence in INSMED INC's long-term prospects.

Risks

• The reporting person, T. Rowe Price Associates, Inc., certified that the securities were acquired and are held in the ordinary course of business and not for the purpose or with the effect of changing or influencing the control of INSMED INC.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders may view the continued significant institutional ownership by T. Rowe Price Associates, Inc. as a positive indicator of long-term value and stability.

Key Dates

Keywords

INSMED INC, T. Rowe Price Associates, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Investment Adviser